Drug guidance
Datopotamab deruxtecan for previously treated unresectable or metastatic HR-positive, HER2-negative breast cancer
Condition
Breast
Cancer
16 September 2025
-
Published on 16 Sep 2025
Last Updated on 16 Sep 2025
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended datopotamab deruxtecan (Dato-DXd) for inclusion on the MOH List of Subsidised Drugs for treating patients with unresectable or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. The decision was based on the unfavourable clinical and cost effectiveness of Dato-DXd compared with chemotherapy, at the price proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for datopotamab deruxtecan are provided in the Annex.